In a retrospective cohort of 28 heavily pretreated metastatic triple-negative breast cancer patients, leronlimab exposure was associated with induction of PD-L1 on circulating tumor and macrophage-like cells, and 17.9% (5/28) of patients remained alive beyond 60 months. Higher leronlimab dose and use in combination or sequence with PD-1/PD-L1 inhibitors tracked with improved survival signals in this dataset.
The core development is a translational package presented at AACR 2026 linking CCR5 inhibition to immune checkpoint modulation in TNBC. Across a broader breast cancer dataset (N=1,096), CCR5 expression correlated with T-cell exhaustion and immune infiltration and was enriched in TNBC subtypes associated with immune modulation. In TNBC models, leronlimab increased PD-L1 expression and attenuated mediators implicated in ICI resistance, including soluble B7-H3 and Tyro3 signaling. In patients, serial liquid-biopsy assessments detected PD-L1 induction post-leronlimab, aligning mechanistically with the preclinical signal and suggesting a potential path to sensitize PD-L1–low tumors to checkpoint therapy.
Strategically, this leans into a “prime-and-combine” thesis to expand the ICI-addressable population in mTNBC, where PD-L1 low status and primary resistance still constrain benefit. Rather than compete as a cytotoxic or targeted monotherapy, leronlimab is being positioned as an immune microenvironment modulator that could convert non-responders and deepen responses to existing ICIs. The dose-response suggestion provides a pharmacologic foothold for Phase 2 design and PK/PD-driven optimization. The tension is evidentiary: the survival signal comes from a small, retrospective experience without a control arm, and the primary biomarker readout is blood-based PD-L1 on CTCs/CAMLs rather than tumor tissue. Any path to registration will need to move from associative mechanistic findings to prospective clinical benefit and satisfy combination “contribution of components” expectations.
For sites and CROs, a next-stage program will likely require serial biospecimen collection, central lab workflows for CTC/CAML enumeration and PD-L1 quantification, and tight assay harmonization across centers. If CytoDyn pursues enrichment in immunomodulatory TNBC subtypes (e.g., MLIA/IM), sites will need upfront molecular subtyping or centralized transcriptomic profiling, adding screening complexity and timelines. Sponsors exploring co-development or supply agreements around PD-1/PD-L1 backbones will weigh factorial or add-on designs to cleanly demonstrate leronlimab’s incremental effect over ICI plus chemotherapy. Regulators will scrutinize how peripheral PD-L1 induction maps to tissue-level changes and objective response, and will expect validated assays and predefined thresholds if PD-L1 conversion is used for stratification or as an intermediate endpoint. Diagnostic and liquid-biopsy vendors could see new demand for standardized CTC/CAML PD-L1 assays and soluble checkpoint panels.
The near-term watch list is straightforward: a prospective combination protocol specifying patient selection (particularly PD-L1–low or ICI-refractory cohorts), dose selection grounded in PD and exposure-response, and an endpoint hierarchy that balances translational markers with ORR, DOR, and PFS. Safety characterization of leronlimab with standard ICIs will need to be defined early. Evidence of tissue-level biomarker conversion, durability of response in ICI-experienced patients, and a clear attribution strategy will determine how quickly the program can advance. A partnership with an ICI incumbent would de-risk drug supply and trial execution, but the bar for a controlled, well-powered signal remains high. If the priming hypothesis replicates prospectively, this could open a pragmatic route to broaden ICI benefit in mTNBC; if not, the translational correlation may remain mechanistically interesting but clinically insufficient.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
